JERUSALEM, December 1, 2010 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that that a customizable ERP compatibility feature has been added to the company's barcoded locking syringe device.
The feature enables a hospital's existing barcoding system to electronically record the administration of a particular medication directly to a patient's medical file.
Using an ERP system, an attending physician or nurse would need only to scan a patient's barcode to view the particular medications and dosages that are required to be administered. Upon scanning the appropriate corresponding barcode on the actual medication, the locking device would open, enabling the administration of the particular syringe.
"Customizing our syringe locking device to work with ERP systems, enables a hospital to keep more accurate records, and eliminates additional possibilities for human error in the administration of medications via syringe," said, Jacob Elhadad, CEO of Medisafe 1 Technologies.
"The combination of the system's simple locking device with state of the art record tracking works to protect hospitals and their patients. We are confident that hospitals will recognize the value of our patented system."
About Medisafe 1 Technologies
Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.
Contact: Jacob Elhadad CEO +972-524440000 Jacob.email@example.com
SOURCE Medisafe 1 Technologies Corp.